STOCK TITAN

Bausch + Lomb Corporation - BLCO STOCK NEWS

Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.

Bausch + Lomb Corporation (BLCO) is a globally recognized leader in the field of eye health, offering comprehensive solutions across three primary business segments: vision care, surgical, and ophthalmic pharmaceuticals. With a history spanning over a century, the company has cemented its reputation as a trusted provider of innovative products and services that address a wide range of eye care needs.

Core Business Segments

Vision Care

The vision care segment encompasses two primary categories: contact lenses and ocular health products. Bausch + Lomb holds a significant share of the global contact lens market, offering a diverse range of lenses tailored to different vision correction needs, including daily disposables, extended-wear lenses, and specialty lenses for astigmatism and presbyopia. Its ocular health products include over-the-counter solutions such as Biotrue and Lumify, which cater to dry eye relief, redness reduction, and overall eye health maintenance.

Surgical

The surgical segment focuses on advanced technologies and equipment designed for ophthalmic procedures. This includes a comprehensive suite of intraocular lenses (IOLs), instruments for cataract and vitreoretinal surgeries, and cutting-edge surgical systems. These solutions are widely used by ophthalmologists to improve patient outcomes in complex eye surgeries, reinforcing Bausch + Lomb's role as a key player in the surgical eye care market.

Ophthalmic Pharmaceuticals

Bausch + Lomb's ophthalmic pharmaceuticals segment features a diverse portfolio of prescription medications that address various eye conditions, including glaucoma, inflammation, and retinal diseases. Notable products include treatments such as Xipere, Vyzulta, and Lotemax. With over 100 prescription eye care products, the company offers one of the most extensive pharmaceutical portfolios in the industry, meeting the needs of both patients and healthcare professionals.

Market Position and Competitive Landscape

Bausch + Lomb operates in the highly competitive eye health and medical device industry, where innovation and trust are paramount. Its competitors include prominent players like Alcon and CooperVision, among others. The company's differentiation lies in its extensive product offerings, longstanding reputation, and commitment to advancing eye care through research and development. By addressing a wide spectrum of eye health needs, Bausch + Lomb has positioned itself as a comprehensive provider in the global market.

Challenges and Opportunities

Operating in a regulated industry, Bausch + Lomb faces challenges such as stringent compliance requirements, pricing pressures, and the need for continuous innovation to stay competitive. However, the company also benefits from opportunities in emerging markets, increasing prevalence of eye conditions, and growing demand for advanced surgical solutions and pharmaceutical treatments. Its ability to adapt to market dynamics and invest in cutting-edge technologies underscores its resilience and growth potential.

Commitment to Eye Health

Bausch + Lomb's mission is deeply rooted in improving lives through better vision. Its investments in research and development, coupled with a focus on quality and safety, reflect its dedication to delivering products that enhance eye health worldwide. As a publicly traded company, Bausch + Lomb continues to build on its legacy of innovation and trust, serving the needs of patients, healthcare providers, and partners across the globe.

Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) announced the appointment of Karen L. Ling to its Board of Directors, with Richard De Schutter retiring following the 2024 Annual Meeting. The Board has temporarily expanded to 11 members and will revert to 10 after the meeting. Karen brings expertise in human capital management and corporate governance, aiming to contribute to the company's growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
management
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) reported strong fourth-quarter and full-year 2023 financial results, with revenue reaching $1.173 billion and $4.146 billion, respectively. Despite a GAAP net loss of $54 million for the quarter and $260 million for the year, adjusted EBITDA stood at $231 million for the quarter and $738 million for the year. Revenue growth was driven by all segments, with a 10% increase for the full year on a reported basis and 12% on a constant currency basis. The company also provided a positive financial outlook for 2024, with projected revenue of $4.600 - $4.700 billion and adjusted EBITDA of $840 - $890 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.78%
Tags
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) has announced the FDA approval of the TENEO Excimer Laser Platform for LASIK vision correction surgery. The platform offers accuracy, efficiency, and usability advantages, with unique features such as advanced eye tracking, high-speed laser, customizable touchscreen, and compact design. It is indicated for patients with myopic astigmatism up to -10.00 D MRSE, 22 years or older, and with stable refraction in the last 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference. Other company executives will also participate. A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
-
Rhea-AI Summary
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced the success of its ONE by ONE and Biotrue Eye Care Recycling programs, collecting 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care, and lens care materials in the United States. This initiative helps keep recyclable plastic and aluminum eye health packaging materials out of landfills and oceans, contributing to environmental sustainability and human health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
Rhea-AI Summary
Bausch + Lomb Corporation reported revenues of $1.007 billion in the third quarter of 2023, a 7% increase compared to the same period last year. The company's GAAP net loss was $84 million. Adjusted EBITDA was $187 million. Revenue growth was driven by the Vision Care and Surgical segments. The company raised its full-year revenue guidance to $4.035 - $4.085 billion and adjusted EBITDA guidance to $710 - $760 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
-
Rhea-AI Summary
Bausch + Lomb to present studies and data at the American Academy of Ophthalmology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb Corporation to release Q3 2023 financial results on Nov. 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
Rhea-AI Summary
Bausch + Lomb to present at AAOpt annual meeting, highlighting the results of a study on Blink Triple Care Lubricating Dry Eye Drops and data on MIEBO prescription eye drops and INFUSE Multifocal contact lenses. Educational events will also be hosted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none

FAQ

What is the current stock price of Bausch + Lomb Corporation (BLCO)?

The current stock price of Bausch + Lomb Corporation (BLCO) is $15.86 as of March 3, 2025.

What is the market cap of Bausch + Lomb Corporation (BLCO)?

The market cap of Bausch + Lomb Corporation (BLCO) is approximately 5.7B.

What does Bausch + Lomb Corporation specialize in?

Bausch + Lomb specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals, offering a wide range of eye health products and services.

What are the main business segments of Bausch + Lomb?

The company operates in three main segments: vision care (contact lenses and ocular health products), surgical (intraocular lenses and surgical equipment), and ophthalmic pharmaceuticals (prescription eye medications).

How does Bausch + Lomb differentiate itself from competitors?

Bausch + Lomb differentiates itself through its extensive product portfolio, longstanding reputation in the industry, and commitment to innovation in eye health solutions.

What challenges does Bausch + Lomb face in its industry?

Challenges include regulatory compliance, pricing pressures, competition from established and emerging players, and the need for continuous innovation to meet market demands.

Who are Bausch + Lomb's key competitors?

Key competitors include companies like Alcon, CooperVision, and other major players in the vision care and ophthalmology sectors.

What is Bausch + Lomb's role in the surgical eye care market?

Bausch + Lomb provides advanced surgical solutions, including intraocular lenses, cataract and vitreoretinal surgical equipment, and instruments, catering to ophthalmologists worldwide.

What makes Bausch + Lomb's pharmaceutical portfolio unique?

With over 100 prescription eye care products, Bausch + Lomb offers one of the most extensive ophthalmic pharmaceutical portfolios, addressing conditions like glaucoma, inflammation, and retinal diseases.

How does Bausch + Lomb generate revenue?

Revenue is generated through direct sales of vision care products, partnerships with healthcare providers for surgical solutions, and sales of prescription medications in the ophthalmic pharmaceuticals segment.

What is Bausch + Lomb's commitment to eye health?

Bausch + Lomb is committed to improving lives through better vision by investing in research, ensuring product quality, and addressing a wide range of eye health needs globally.

What opportunities exist for Bausch + Lomb in the market?

Opportunities include expanding into emerging markets, addressing the increasing prevalence of eye conditions, and meeting growing demand for advanced surgical and pharmaceutical solutions.
Bausch + Lomb Corporation

NYSE:BLCO

BLCO Rankings

BLCO Stock Data

5.65B
40.60M
88.44%
11.12%
0.36%
Medical Instruments & Supplies
Ophthalmic Goods
Link
Canada
VAUGHAN